Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03281304
Registration number
NCT03281304
Ethics application status
Date submitted
11/09/2017
Date registered
13/09/2017
Date last updated
21/03/2023
Titles & IDs
Public title
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
Query!
Scientific title
A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION
Query!
Secondary ID [1]
0
0
RIVETING STUDY
Query!
Secondary ID [2]
0
0
A3921288
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - CP-690,500 5 mg
Treatment: Drugs - CP-690,550 10 mg
Experimental: CP-690,550 5 mg - CP-690,550 5 mg tablet by mouth twice a day (BID)
Experimental: CP-690,550 10 mg - CP-690,550 10 mg BID
Treatment: Drugs: CP-690,500 5 mg
CP-690,550 5 mg tablet BID
Treatment: Drugs: CP-690,550 10 mg
CP-690,550 10 mg tablet BID
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Remission Based on Modified Mayo Score at Month 6
Query!
Assessment method [1]
0
0
Remission as per modified mayo score was defined as an endoscopic subscore of 0 or 1, stool frequency subscore of 0 or 1, and rectal bleeding subscore of 0 at Month 6. Modified mayo score consisted of 3 components: stool frequency subscore, rectal bleeding subscore and endoscopic subscore: higher scores for each score = more severe disease. These scores were summed up to give a total modified mayo score range of 0 to 9; where higher scores indicating more severe disease.
Query!
Timepoint [1]
0
0
Month 6
Query!
Secondary outcome [1]
0
0
Time to Loss of Remission Based on Modified Mayo Score Using Kaplan-Meier Method
Query!
Assessment method [1]
0
0
Time to loss of remission(flare): time from first drug administration until time of meeting loss of remission criteria based on modified mayo score. Loss of remission: meeting at least (>=)1 criteria: increase from Baseline in rectal bleeding subscore by >=1 point and increase in endoscopic subscore by >=1 point; increase from Baseline in rectal bleeding subscore by >=2 points and endoscopic subscore >0; increase in stool frequency subscore by >=2 points and increase in endoscopic subscore by >=1 point; increase in endoscopic subscore by >=2 points. Modified mayo score included 3 components: stool frequency, rectal bleeding and endoscopic subscores: Modified mayo score included 3 components: stool frequency, rectal bleeding and endoscopic subscores, each subscore graded from 0 to 3 with higher scores for each score=more severe disease. All scores summed up to give total modified mayo score range from 0 to 9; higher scores=more severe disease.
Query!
Timepoint [1]
0
0
Up to Month 42
Query!
Secondary outcome [2]
0
0
Number of Participants With Remission Based on Modified Partial Mayo Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Assessment method [2]
0
0
Remission as per modified partial mayo score was defined as stool frequency subscore of 0 or 1, and rectal bleeding sub score of 0 at the specified time points. Modified partial mayo scores consisted of 2 components: stool frequency and rectal bleeding: each subscore graded from 0 to 3 with higher scores for each score = more severe disease. These scores were summed up to give a total modified partial mayo score range of 0 to 6; where higher scores indicating more severe disease.
Query!
Timepoint [2]
0
0
Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Secondary outcome [3]
0
0
Number of Participants With Remission Based on Total Mayo Score at Months 6, 18, 30 and 42
Query!
Assessment method [3]
0
0
Remission as per total mayo score was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and physician global assessment (PGA), each subscore graded from 0 to 3 with higher scores indicating more severe disease. PGA included 3 criteria: participant's recollection of abdominal discomfort, general sense of wellbeing and other observations such as physical findings and performance status. Individual subscores were summed up to give a total mayo score range of 0 to 12, where higher scores indicating more severe disease.
Query!
Timepoint [3]
0
0
Months 6, 18, 30 and 42
Query!
Secondary outcome [4]
0
0
Number of Participants With Remission Based on Partial Mayo Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Assessment method [4]
0
0
Remission as per partial mayo score was defined as partial mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Partial mayo score was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 subscores: stool frequency, rectal bleeding and PGA with each subscore graded from 0 to 3 with higher scores indicating more severe disease. PGA included 3 criteria: participant's recollection of abdominal discomfort, general sense of wellbeing and other observations such as physical findings and performance status. Individual subscores were summed up to give a total partial mayo score range from 0 (normal or inactive disease) to 9 (severe disease) with higher scores indicating more severe disease.
Query!
Timepoint [4]
0
0
Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Secondary outcome [5]
0
0
Number of Participants With Remission Based on Modified Mayo Score at Months 18, 30 and 42
Query!
Assessment method [5]
0
0
Remission as per modified mayo score was defined as an endoscopic subscore of 0 or 1, stool frequency subscore of 0 or 1, and rectal bleeding subscore of 0. Modified mayo score consisted of 3 components: stool frequency subscore, rectal bleeding subscore and endoscopic subscore: higher scores for each score = more severe disease. These scores were summed up to give a total modified mayo score range of 0 to 9; where higher scores indicating more severe disease.
Query!
Timepoint [5]
0
0
Months 18, 30 and 42
Query!
Secondary outcome [6]
0
0
Change From Baseline in Modified Mayo Score at Month 6
Query!
Assessment method [6]
0
0
Modified mayo score is an instrument designed to measure disease activity of UC. Modified mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 to 3 with higher scores indicating more severe disease. These individual scores were summed up to give a total modified mayo score range of 0 to 9, where higher scores indicated more severe disease.
Query!
Timepoint [6]
0
0
Baseline, Month 6
Query!
Secondary outcome [7]
0
0
Change From Baseline in Modified Mayo Score at Months 18, 30 and 42
Query!
Assessment method [7]
0
0
Modified mayo score is an instrument designed to measure disease activity of UC. Modified mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 to 3 with higher scores indicating more severe disease. These individual scores were summed up to give a total modified mayo score range of 0 to 9, where higher scores indicated more severe disease.
Query!
Timepoint [7]
0
0
Baseline, Months 18, 30 and 42
Query!
Secondary outcome [8]
0
0
Change From Baseline in Modified Partial Mayo Score at Months 1, 3 and 6
Query!
Assessment method [8]
0
0
Modified partial mayo scores consisted of 2 subscores: stool frequency and rectal bleeding with each subscore graded from 0 to 3 with higher scores indicating more severe disease. Individual subscores were summed up to give a total Modified partial mayo score ranges from 0 (normal or inactive disease) to 6 (severe disease) with higher scores indicating more severe disease.
Query!
Timepoint [8]
0
0
Baseline, Months 1, 3 and 6
Query!
Secondary outcome [9]
0
0
Change From Baseline in Modified Partial Mayo Score at Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Assessment method [9]
0
0
Modified partial mayo scores consisted of 2 subscores: stool frequency and rectal bleeding with each subscore graded from 0 to 3 with higher scores indicating more severe disease. Individual subscores were summed up to give a total modified partial mayo score range from 0 (normal or inactive disease) to 6 (severe disease) with higher scores indicating more severe disease.
Query!
Timepoint [9]
0
0
Baseline, Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Secondary outcome [10]
0
0
Change From Baseline in Total Mayo Score at Month 6
Query!
Assessment method [10]
0
0
Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicating more severe disease. PGA included 3 criteria: participant's recollection of abdominal discomfort, general sense of wellbeing and other observations such as physical findings and performance status. Individual subscores were summed up to give a total mayo score range of 0 to 12, where higher scores indicating more severe disease.
Query!
Timepoint [10]
0
0
Baseline, Month 6
Query!
Secondary outcome [11]
0
0
Change From Baseline in Total Mayo Score at Months 18, 30 and 42
Query!
Assessment method [11]
0
0
Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicating more severe disease. PGA included 3 criteria: participant's recollection of abdominal discomfort, general sense of wellbeing and other observations such as physical findings and performance status. Individual subscores were summed up to give a total mayo score range of 0 to 12, where higher scores indicating more severe disease.
Query!
Timepoint [11]
0
0
Baseline, Months 18, 30 and 42
Query!
Secondary outcome [12]
0
0
Change From Baseline in Partial Mayo Score at Months 1, 3 and 6
Query!
Assessment method [12]
0
0
Partial mayo score was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 subscores: stool frequency, rectal bleeding and PGA with each subscore graded from 0 to 3 with higher scores indicating more severe disease. PGA included 3 criteria: participant's recollection of abdominal discomfort, general sense of wellbeing and other observations such as physical findings and performance status. Individual subscores were summed up to give a total partial mayo score range from 0 (normal or inactive disease) to 9 (severe disease) with higher scores indicating more severe disease.
Query!
Timepoint [12]
0
0
Baseline, Months 1, 3 and 6
Query!
Secondary outcome [13]
0
0
Change From Baseline in Partial Mayo Score at Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Assessment method [13]
0
0
Partial mayo score was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 subscores: stool frequency, rectal bleeding and PGA with each subscore graded from 0 to 3 with higher scores indicating more severe disease. PGA included 3 criteria: participant's recollection of abdominal discomfort, general sense of wellbeing and other observations such as physical findings and performance status. Individual subscores were summed up to give a total partial mayo score ranges from 0 (normal or inactive disease) to 9 (severe disease) with higher scores indicating more severe disease.
Query!
Timepoint [13]
0
0
Baseline, Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Secondary outcome [14]
0
0
Number of Participants With Mucosal Healing at Months 6, 18, 30 and 42
Query!
Assessment method [14]
0
0
Mucosal healing in participants was defined as the mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicated more severe disease.
Query!
Timepoint [14]
0
0
Months 6, 18, 30 and 42
Query!
Secondary outcome [15]
0
0
Number of Participants With Clinical Response Based on Mayo Score at Months 6, 18, 30 and 42
Query!
Assessment method [15]
0
0
Clinical response was defined as a decrease from baseline in mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicating more severe disease. PGA included 3 criteria: participant's recollection of abdominal discomfort, general sense of wellbeing and other observations such as physical findings and performance status. Individual subscores were summed up to give a mayo score range of 0 to 12, where higher scores indicating more severe disease.
Query!
Timepoint [15]
0
0
Months 6, 18, 30 and 42
Query!
Secondary outcome [16]
0
0
Change From Baseline in Fecal Calprotectin at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Assessment method [16]
0
0
Change from baseline in fecal calprotectin (in micrograms per gram [mcg/g]) was reported.
Query!
Timepoint [16]
0
0
Baseline, Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Secondary outcome [17]
0
0
Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Level at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Assessment method [17]
0
0
Change From baseline in hs-CRP level (in milligrams per liter [mg/L]) is reported.
Query!
Timepoint [17]
0
0
Baseline, Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Query!
Secondary outcome [18]
0
0
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [18]
0
0
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events (irrespective of frequency threshold used to report other AEs in safety section).
Query!
Timepoint [18]
0
0
Baseline up to 43 months
Query!
Secondary outcome [19]
0
0
Number of Participants With Serious Infections
Query!
Assessment method [19]
0
0
Serious infections were defined as any infections (viral, bacterial, and fungal) requiring parenteral antimicrobial therapy, hospitalization for treatment, or meeting other criteria that require the infection to be classified as serious adverse event. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events.
Query!
Timepoint [19]
0
0
Baseline up to 43 months
Query!
Secondary outcome [20]
0
0
Number of Participants With Clinical Laboratory Abnormalities
Query!
Assessment method [20]
0
0
Abnormality criteria: Hematology: hemoglobin(Hg): <0.8* lower limit of normal (LLN); hematocrit: <0.8*LLN; lymphocytes: <0.8* LLN; lymphocytes/leukocytes: <0.8*LLN; erythrocytes: <0.8*LLN; erythrocytes mean corpuscular volume: <0.9*LLN; erythrocytes mean corpuscular Hg: <0.9*LLN; reticulocytes, reticulocytes/erythrocytes:>1.5* upper limit of normal (ULN); neutrophils, neutrophils/leukocytes: >1.2*ULN; basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes/leukocytes: >1.2*ULN; leukocyte esterase: >=1; Clinical chemistry: bicarbonate:<0.9*LLN, bilirubin: >1.5*ULN; indirect bilirubin: >1.5* ULN; aspartate aminotransferase(AT): >3.0*ULN; alanine AT: >3.0*ULN; gamma glutamyl transferase: >3.0* ULN; creatine kinase: >2.0*ULN; potassium: >1.1*ULN; blood urea nitrogen: >1.3*ULN; creatinine: >1.3*ULN; urate: >1.2*ULN; cholesterol: >1.3*ULN; HDL-cholesterol: <0.8* LLN; LDL-cholesterol: >1.2*ULN; triglycerides: >1.3*ULN; glucose: >1.5*ULN; and urine Hg >=1.
Query!
Timepoint [20]
0
0
Baseline up to 27 months
Query!
Secondary outcome [21]
0
0
Number of Participants With Clinically Significant Laboratory Abnormalities Leading to Study Treatment Discontinuation
Query!
Assessment method [21]
0
0
Laboratory abnormalities leading to study treatment discontinuation: 2 sequential neutrophil counts <750 neutrophils per cubic millimeter (mm^3); 2 sequential lymphocyte counts <500 lymphocytes/mm^3; 2 sequential hemoglobin <8.0 grams per deciliter; 2 sequential platelet counts <75000 platelets/mm^3; 2 sequential AST or ALT elevations >=3*ULN with at least one total bilirubin value >=2*ULN; 2 sequential AST or ALT elevations >=3*ULN accompanied by signs or symptoms consistent with hepatic injury; 2 sequential AST or ALT elevations >=5*ULN; 2 sequential increases in creatinine >50% and >0.5 milligrams per deciliter over A3921139 baseline; 2 sequential CK elevations >10*ULN unless the causality is known not to be medically serious (eg, exercise induced).
Query!
Timepoint [21]
0
0
Baseline up to 43 months
Query!
Secondary outcome [22]
0
0
Number of Participants With Vital Sign Abnormalities
Query!
Assessment method [22]
0
0
Vital signs abnormality criteria included: 1) a) diastolic blood pressure (DBP) of (less than) <50 millimeter of mercury (mmHg), b) change greater than equal to (>=) 20 mmHg increase, c) change >=20 mmHg decrease; 2) a) systolic blood pressure (SBP) of <90 mmHg, b) change >=30 mmHg increase, c) change >=30 mmHg decrease; 3) a) pulse rate value of <40 beats per minute (bpm), b) pulse rate >120 bpm. Only those categories in which at least 1 participant had data were reported.
Query!
Timepoint [22]
0
0
Baseline up to 43 months
Query!
Secondary outcome [23]
0
0
Number of Participants With Clinically Significant Physical Examinations Abnormalities
Query!
Assessment method [23]
0
0
Physical examination included assessment of the weight, general appearance, eyes, mouth, lungs, heart, abdomen, musculoskeletal, extremities, skin and lymph nodes. Clinical significance was assessed by the Investigator.
Query!
Timepoint [23]
0
0
Baseline up to 43 months
Query!
Secondary outcome [24]
0
0
Number of Participants With Opportunistic Infections, All Malignancy, Gastrointestinal Perforation and Cardiovascular Events Adjudicated by Adjudication Committee
Query!
Assessment method [24]
0
0
Number of participants with adjudicated opportunistic infections including herpes zoster (non-adjacent or >2 adjacent dermatomes); all malignancies including non-melanoma skin cancer; gastrointestinal perforation and cardiovascular events including pulmonary embolism and cerebrovascular accident, adjudicated by adjudication committee were reported.
Query!
Timepoint [24]
0
0
Baseline up to 43 months
Query!
Eligibility
Key inclusion criteria
- Currently enrolled in Study A3921139 receiving CP-690,550 10 mg BID for at least 2
years consecutively.
- In stable remission on CP-690,550 10 mg BID
- Agree to use highly effective contraception
- Negative pregnancy test
- Comply with visits, treatments, lab tests, diary and other study procedures
- Signed and dated informed consent document.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects who were initially assigned to tofacitinib 10 mg BID at baseline of Study
A3921139 whose tofacitinib dose was reduced to 5 mg BID due to safety or efficacy.
- Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious
colitis or findings suggestive of Crohn's disease
- Likely to require surgery for ulcerative colitis during study
- Expected to receive any prohibited medication
- Expected to receive live or attenuated virus vaccination during study
- Women who are pregnant or breastfeeding or planning to become pregnant during the
study
- Evidence of colonic malignancy or any dysplasia
- Acute or chronic medical or psychiatric condition that may increase risk of
participation
- Investigator site staff member
- Subjects likely to be uncooperative or unable to comply with study procedures
- Participation in other studies involving investigational drugs during study
- Subjects with any of the following risk factors for pulmonary embolism at baseline as
defined by EMA's PRAC:
- has heart failure;
- has inherited coagulation disorders;
- has had venous thromboembolism, either deep venous thrombosis or pulmonary
embolism;
- is taking combined hormonal contraceptives or hormone replacement therapy;
- has malignancy (association is strongest with cancers other than non-melanoma
skin cancers);
- is undergoing major surgery
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/11/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/03/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
140
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Utah
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Leuven
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Ontario
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Saskatchewan
Query!
Country [15]
0
0
Czechia
Query!
State/province [15]
0
0
Strakonice
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Nantes
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Pessac
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Kiel
Query!
Country [19]
0
0
Hungary
Query!
State/province [19]
0
0
Budapest
Query!
Country [20]
0
0
Hungary
Query!
State/province [20]
0
0
Gyula
Query!
Country [21]
0
0
Italy
Query!
State/province [21]
0
0
CZ
Query!
Country [22]
0
0
Japan
Query!
State/province [22]
0
0
Aichi
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Fukuoka
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Hokkaido
Query!
Country [25]
0
0
Japan
Query!
State/province [25]
0
0
Osaka
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Shiga
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Tokyo
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Chiba
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Hiroshima
Query!
Country [30]
0
0
Korea, Republic of
Query!
State/province [30]
0
0
Gyeonggi-do
Query!
Country [31]
0
0
Korea, Republic of
Query!
State/province [31]
0
0
Seoul
Query!
Country [32]
0
0
Netherlands
Query!
State/province [32]
0
0
Amsterdam
Query!
Country [33]
0
0
New Zealand
Query!
State/province [33]
0
0
Auckland
Query!
Country [34]
0
0
New Zealand
Query!
State/province [34]
0
0
Christchurch
Query!
Country [35]
0
0
New Zealand
Query!
State/province [35]
0
0
Dunedin
Query!
Country [36]
0
0
Poland
Query!
State/province [36]
0
0
Sopot
Query!
Country [37]
0
0
Poland
Query!
State/province [37]
0
0
Wroclaw
Query!
Country [38]
0
0
Russian Federation
Query!
State/province [38]
0
0
Moscow
Query!
Country [39]
0
0
Russian Federation
Query!
State/province [39]
0
0
Novosibirsk
Query!
Country [40]
0
0
Serbia
Query!
State/province [40]
0
0
Belgrade
Query!
Country [41]
0
0
Serbia
Query!
State/province [41]
0
0
Kragujevac
Query!
Country [42]
0
0
Serbia
Query!
State/province [42]
0
0
Zrenjanin
Query!
Country [43]
0
0
Slovakia
Query!
State/province [43]
0
0
Bratislava
Query!
Country [44]
0
0
Slovakia
Query!
State/province [44]
0
0
Nitra
Query!
Country [45]
0
0
Slovakia
Query!
State/province [45]
0
0
Presov
Query!
Country [46]
0
0
South Africa
Query!
State/province [46]
0
0
Cape Town
Query!
Country [47]
0
0
South Africa
Query!
State/province [47]
0
0
Johannesburg, Gauteng
Query!
Country [48]
0
0
South Africa
Query!
State/province [48]
0
0
Johannesburg
Query!
Country [49]
0
0
South Africa
Query!
State/province [49]
0
0
Western CAPE
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Barcelona
Query!
Country [51]
0
0
Ukraine
Query!
State/province [51]
0
0
Chernivtsi
Query!
Country [52]
0
0
Ukraine
Query!
State/province [52]
0
0
Kyiv
Query!
Country [53]
0
0
Ukraine
Query!
State/province [53]
0
0
Uzhgorod
Query!
Country [54]
0
0
Ukraine
Query!
State/province [54]
0
0
Vinnytsia
Query!
Country [55]
0
0
United Kingdom
Query!
State/province [55]
0
0
Avon
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission
designed to evaluate flexible dosing of CP-690,550.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03281304
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03281304
Download to PDF